Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| UAS protocol #1 | Other Grant/Funding Number | United Allergy Services |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Hypothesis: The UAS Immunotherapy protocol is efficacious and at least as efficacious as protocols described in the Allergy literature.
Patients will be assessed for efficacy of the immunotherapy protocol by completing Consented-IRB approved clinical, medication, quality of life survey questions comparing current status while on therapy in contrast to 12 months before the inception of therapy.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| allergen immunotherapy | Other | allergy shots |
|
| Measure | Description | Time Frame |
|---|---|---|
| change in symptom scores from 12 months before therapy initiation in contrast to determination during 1 to 2 years of therapy (retrospective). | Enrolled patients completed surveys pertinent to symptom scores, contrasting current status on immunotherapy compared (by recall) to a 12 month time point prior to initiation of therapy. | Assessment contrasts current status (at 1 to 2 years of therapy) to a point 12 months prior to the onset of therapy. |
| Measure | Description | Time Frame |
|---|---|---|
| Changes in medication plus symptom aggregate score. | Aggregate Medication and Symptom surveys were compared to determine changes from a 12 month time point prior to inception of therapy to current time point of 1 to 2 years of therapy. | Assessment contrasts current status (at 1 to 2 years of therapy) to a point 12 months prior to the onset of therapy. |
| Measure | Description | Time Frame |
|---|---|---|
| Quality of Life (QOL) scores | QOL scores will be calculated after one to 2 years of therapy and contrasted with QOL reflecting status 12 months prior to initiation of therapy. | Assessment contrasts current status (at 1 to 2 years of therapy) to a point 12 months prior to the onset of therapy |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Patients with allergic rhinitis pre and post immunotherapy (1 to 2 years).
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Frederick M Schaffer, M.D. | United Allergy Services | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| UAS | San Antonio | Texas | 78216 | United States |
Not provided
| ID | Term |
|---|---|
| D065631 | Rhinitis, Allergic |
| ID | Term |
|---|---|
| D012220 | Rhinitis |
| D009668 | Nose Diseases |
| D012140 | Respiratory Tract Diseases |
| D012130 | Respiratory Hypersensitivity |
Not provided
Not provided
| ID | Term |
|---|---|
| D003888 | Desensitization, Immunologic |
| ID | Term |
|---|---|
| D007165 | Immunosuppression Therapy |
| D007167 | Immunotherapy |
| D056747 | Immunomodulation |
| D001691 | Biological Therapy |
Not provided
Not provided
Not provided
Not provided
Not provided
| D010038 |
| Otorhinolaryngologic Diseases |
| D006969 | Hypersensitivity, Immediate |
| D006967 | Hypersensitivity |
| D007154 | Immune System Diseases |
| D013812 |
| Therapeutics |
| D007158 | Immunologic Techniques |
| D008919 | Investigative Techniques |